Neshro Barmano1,2, Emmanouil Charitakis2,3, Jan-Erik Karlsson1,2, Fredrik H Nystrom2,4, Håkan Walfridsson2,3, Ulla Walfridsson2,3. 1. Department of Internal Medicine, County Hospital Ryhov, Jönköping, Sweden. 2. Department of Medical and Health Sciences, Linköping University, Linköping, Sweden. 3. Department of Cardiology, Linköping University Hospital, Linköping, Sweden. 4. Primary Health Care Centre Centrum, Norrköping, Sweden.
Abstract
BACKGROUND: The primary goal of radiofrequency ablation (RFA) of atrial fibrillation (AF) is to improve symptoms and health-related quality of life (HRQoL). However, most studies have focused on predictors of AF recurrence rather than on predictors of improvement in symptoms and HRQoL. HYPOTHESIS: We sought to explore predictors of improvement in arrhythmia-specific symptoms and HRQoL after RFA of AF, and to evaluate the effects on symptoms, HRQoL, anxiety, and depression. METHODS: We studied 192 patients undergoing their first RFA of AF. The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), arrhythmia-specific questionnaire in tachycardia and arrhythmia (ASTA), and hospital anxiety and depression scale (HADS) questionnaires were filled out at baseline, at 4 months, and at a 1-year follow-up. RESULTS: All questionnaire scale scores improved significantly over time. In the ASTA symptom scale score, female gender and > 10 AF episodes the month before RFA were significant positive predictors of improvement, while diabetes and AF recurrence within 12 months after RFA were significant negative predictors (R2 = 0.18; P < 0.001). In the ASTA HRQoL scale score, the presence of heart failure and > 10 AF episodes the month before RFA were significant positive predictors of improvement, while diabetes, maximum left atrial volume and AF recurrence were significant negative predictors (R2 = 0.20; P < 0.001). CONCLUSION: Left atrial volume, gender, diabetes, heart failure, the frequency of AF attacks prior to RFA, and recurrence of AF after RFA were significant factors affecting improvement in symptoms and HRQoL after RFA of AF. Future studies are warranted to confirm these findings.
BACKGROUND: The primary goal of radiofrequency ablation (RFA) of atrial fibrillation (AF) is to improve symptoms and health-related quality of life (HRQoL). However, most studies have focused on predictors of AF recurrence rather than on predictors of improvement in symptoms and HRQoL. HYPOTHESIS: We sought to explore predictors of improvement in arrhythmia-specific symptoms and HRQoL after RFA of AF, and to evaluate the effects on symptoms, HRQoL, anxiety, and depression. METHODS: We studied 192 patients undergoing their first RFA of AF. The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), arrhythmia-specific questionnaire in tachycardia and arrhythmia (ASTA), and hospital anxiety and depression scale (HADS) questionnaires were filled out at baseline, at 4 months, and at a 1-year follow-up. RESULTS: All questionnaire scale scores improved significantly over time. In the ASTA symptom scale score, female gender and > 10 AF episodes the month before RFA were significant positive predictors of improvement, while diabetes and AF recurrence within 12 months after RFA were significant negative predictors (R2 = 0.18; P < 0.001). In the ASTA HRQoL scale score, the presence of heart failure and > 10 AF episodes the month before RFA were significant positive predictors of improvement, while diabetes, maximum left atrial volume and AF recurrence were significant negative predictors (R2 = 0.20; P < 0.001). CONCLUSION: Left atrial volume, gender, diabetes, heart failure, the frequency of AF attacks prior to RFA, and recurrence of AF after RFA were significant factors affecting improvement in symptoms and HRQoL after RFA of AF. Future studies are warranted to confirm these findings.
Authors: F D'Ascenzo; A Corleto; G Biondi-Zoccai; M Anselmino; F Ferraris; L di Biase; A Natale; R J Hunter; R J Schilling; S Miyazaki; H Tada; K Aonuma; L Yenn-Jiang; H Tao; C Ma; D Packer; S Hammill; F Gaita Journal: Int J Cardiol Date: 2012-05-22 Impact factor: 4.164
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: Sanghamitra Mohanty; Prasant Mohanty; Luigi Di Biase; Rong Bai; Agnes Pump; Pasquale Santangeli; David Burkhardt; Joseph G Gallinghouse; Rodney Horton; Javier E Sanchez; Shane Bailey; Jason Zagrodzky; Andrea Natale Journal: J Am Coll Cardiol Date: 2012-04-03 Impact factor: 24.094
Authors: João Mesquita; António Miguel Ferreira; Diogo Cavaco; Francisco Moscoso Costa; Pedro Carmo; Hugo Marques; Francisco Morgado; Miguel Mendes; Pedro Adragão Journal: Europace Date: 2018-11-01 Impact factor: 5.214
Authors: A Sultan; J Lüker; D Andresen; K H Kuck; E Hoffmann; J Brachmann; M Hochadel; S Willems; L Eckardt; T Lewalter; J Senges; D Steven Journal: Sci Rep Date: 2017-11-30 Impact factor: 4.379
Authors: Ulla Walfridsson; Anders Hassel Jönsson; Lars O Karlsson; Ioan Liuba; Henrik Almroth; Emma Sandgren; Håkan Walfridsson; Emmanouil Charitakis Journal: Clin Cardiol Date: 2021-12-16 Impact factor: 2.882
Authors: Monika Sadlonova; Jochen Senges; Jonas Nagel; Christopher Celano; Caroline Klasen-Max; Martin Borggrefe; Ibrahim Akin; Dierk Thomas; Christopher Jan Schwarzbach; Thomas Kleeman; Steffen Schneider; Matthias Hochadel; Tim Süselbeck; Harald Schwacke; Angelika Alonso; Markus Haass; Karl-Heinz Ladwig; Christoph Herrmann-Lingen Journal: J Clin Med Date: 2022-02-21 Impact factor: 4.241